Clinical trials: Adalimumab, open to volunteers
Non-infectious Anterior Uveitis, Non-infectious Intermediate Uveitis
Efficacy and Safety of Adalimumab for the Treatment of Ocular Inflammation
This study aims to evaluate the clinical efficacy and safety of adalimumab in pediatric non-infectious uveitis and to generate domestic real-world evidence (RWE), thereby establishing a clinical foundation for label expansion and…
- Conditions
- Non-infectious Anterior Uveitis, Non-infectious Intermediate Uveitis, Non-infectious Posterior Uveitis, Panuveitis
- Trial name
- PANDA-U (NCT07913750)
- Testing
- Adalimumab PFS and Pen
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Samsung Medical Center
REM Sleep Behavior Disorder
An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)
This is a phase 2 study to assess the ability of adalimumab as compared to placebo to reduce or prevent progression of synuclein-related neurodegeneration in persons with idiopathic REM Sleep Behavior Disorder (RBD).
- Trial name
- PRISMS (NCT06996652)
- Testing
- Adalimumab
- Where
- 18 sites in United States, Canada
- Volunteers
- 108 people
- Sponsor
- Yale University
Juvenile Idiopathic Arthritis (JIA)
Withdrawal Versus Continued TNF Inhibitor Monotherapy Treatment in Children With Inactive Juvenile Idiopathic Arthritis
The goal of this clinical trial is to learn whether children and adolescents with juvenile idiopathic arthritis (JIA) who have had inactive disease for a long time can safely discontinue treatment with a tumour necrosis factor…
- Trial name
- The Treat-JIA (NCT07904780)
- Testing
- Adalimumab, Etanercept, Golimumab
- Where
- 3 sites in Norway
- Volunteers
- 90 people
- Sponsor
- Oslo University Hospital
Crohn Disease
PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease
There are currently three classes of biologic treatments approved in Canada for the management of moderate-to-severe Crohn's disease: anti-tumor necrosis factor [TNF] alpha, anti-integrin, and anti-interleukin [IL]-23 targeted…
- Trial name
- PATHFINDER (NCT05928039)
- Testing
- TNFa Antagonist - Infliximab, TNFa Antagonist - Adalimumab, Anti-IL12/23 or anti-IL23 - Ustekinumab
- Where
- 23 sites in Canada
- Volunteers
- 210 people
- Sponsor
- University of Calgary
Type 1 Diabetes, New Onset
A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes
This multi-center randomized controlled trial will assess the safety and efficacy of ATG followed by either adalimumab or verapamil in preserving insulin secretion 2 years from randomization in persons aged 9 to <21 with…
- Trial name
- WAVE T1D (NCT07061574)
- Testing
- Anti-thymocyte globulin (ATG), verapamil extended-release capsule, Adalimumab
- Where
- 11 sites in United States
- Volunteers
- 120 people
- Sponsor
- City of Hope Medical Center
Major Depressive Disorder (MDD)
Precision Depression Adalimumab Trial
The goal of this clinical trial is to learn if the anti-inflammatory medication adalimumab improves depressive symptoms in adults with Major Depressive Disorder (MDD) who are already taking the anti-depressant medication Lexapro…
- Trial name
- PDAT (NCT07845604)
- Testing
- Adalimumab Biosimilars Injection
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Daniel Moriarity
Crohn's Disease
Treatment of Chinese Adult Subjects With Moderate to Severe Crohn's Disease With Tabellvi®
This is a post-marketing real-world study designed to evaluate the efficacy and safety of Tabellvi® (Adalimumab Injection) in Chinese adult subjects with moderate to severe active Crohn's disease via a single-arm trial.
- Trial name
- NCT07663526
- Testing
- TyboWe® Adalimumab Injection
- Where
- 7 sites in China
- Volunteers
- 50 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Axial or Predominantly Axial SpondyloArthritis With or Without Psoriasis
Evaluation of the Efficacy and Safety of Bimekizumab (BZK) or Adalimumab (ADA) in the Treatment of Anterior Chest Wall Pain Associated With Active Axial Spondyloarthritis Refractory to NSAIDs With Hypothesis of Superiority of Bimekizumab
The primary objective is to demonstrate the superiority of BKZ (dual inhibition of IL-17A and IL-17F) on the ASAS40 response at 6 months compared to a reference treatment (ADA) in patients with active axial or predominantly axial…
- Trial name
- ThoracSPA (NCT07836283)
- Testing
- bimekizumab, adalimumab
- Where
- France
- Volunteers
- 150 people
- Sponsor
- University Hospital, Rouen
Behcet Syndrome, Intestinal Type
Baricitinib in the Treatment of Intestinal Behçet's Syndrome
This study aims to conduct a randomized controlled trial to compare the efficacy and safety of Baricitinib and Adalimumab (ADA) in the treatment of refractory intestinal Behçet's Syndrome (BS).
- Trial name
- NCT06849908
- Testing
- Baricitinib, Adalimumab
- Where
- 2 sites in China
- Volunteers
- 56 people
- Sponsor
- Peking Union Medical College Hospital
Rectal Cancers
Neoadjuvant Radiotherapy Combined With NALIRIFOX and Adebrelimab in pMMR/MSS Locally Advanced Rectal Cancer: A Prospective, Randomized, Phase II Clinical Trial
To explore the efficacy and safety of radiotherapy combined with Adebrelimab and NALIRIFOX in patients with pMMR/MSS locally advanced rectal cancer
- Trial name
- NCT07622771
- Testing
- Adalimumab+NALIRIFOX→Short course radiotherapy →Adalimumab+NALIRIFOX, Adalimumab+NALIRIFOX→Long course chemoradiotherapy →Adalimumab+NALIRIFOX
- Where
- China
- Volunteers
- 84 people
- Sponsor
- Sun Yat-sen University
Children Aged 6 Years and Above With Moderate - to - Severe Active Crohn's Disease
A Clinical Trial of Taibowei® Adalimumab Injection in the Treatment of Chinese Pediatric Patients With Moderately to Severely Active Crohn's Disease
This study is a real - world clinical research of adalimumab. The project plans to enroll 30 subjects, aiming to evaluate the incidence of serious adverse events (SAEs) within 12, 26, and 52 weeks after treatment; as well as the…
- Trial name
- NCT07564505
- Testing
- Adalimumab Solution for Injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Psoriatic Arthritis, Ultrasound Assessment
Apremilast and Adalimumab in Psoriatic Arthritis Patients
The aim of this work is to compare the efficacy of Apremilast combined with Methotrexate versus Adalimumab combined with Methotrexate
- Conditions
- Psoriatic Arthritis, Ultrasound Assessment, TNF
- Trial name
- NCT07398651
- Testing
- Adalimumab, Apremilast
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Tanta University
Relapsing Polychondritis
Pragmatic, Open-Label Study to Pilot Evaluation for Clinical Trials in Relapsing Polychondritis
Open label pragmatic two-stage non-randomized trial comparing the effectiveness of five different standard of care treatment options for patients with relapsing polychondritis (RP).
- Trial name
- PROSECT RP (NCT06941376)
- Testing
- Methotrexate (MTX), Azathioprine (AZA), Adalimumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Pennsylvania
Juvenile Psoriatic Arthritis
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
Psoriatic arthritis (PsA) is a type of arthritis that happens when the body's immune system attacks healthy cells and tissues causing joint pain, stiffness, and swelling. Symptoms can get worse and go away for periods of time.
- Trial name
- NCT06100744
- Testing
- Adalimumab, Risankizumab
- Where
- 34 sites in United States, Australia and 7 more
- Volunteers
- 40 people
- Sponsor
- AbbVie
Penetrating Keratoplasty, Multiple Graft Failure
Subconjunctival Humira for Boston Keratoprosthesis
This trial is studying the safety and tolerability of receiving an injection of adalimumab (Humira) during the Boston Keratoprosthesis (KPro) surgery.
- Conditions
- Penetrating Keratoplasty, Multiple Graft Failure, Ocular Cicatricial Pemphigoid, Stevens-Johnson Syndrome
- Trial name
- NCT06926478
- Testing
- Adalimumab Injection
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Massachusetts Eye and Ear Infirmary
Healthy Subjects
A Study to Investigate How Well an Intracolonic Formulation of Two Monoclonal Antibodies is Tolerated in Healthy Participants and the Ability for the Antibodies to be Taken up by the Body Via the Colon
This is a proof-of-concept study to investigate whether antibodies (guselkumab and adalimumab) delivered directly to the colon can enter the systemic circulation.
- Trial name
- NCT07788807
- Testing
- Adalimumab, Guselkumab, SDL-001
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Surmount Services, Inc.
Arthritis, Rheumatoid
Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis
The goal of this N-of-1 study is to learn about treatment for individual patients who have rheumatoid arthritis (RA,) for which many treatments are available.
- Trial name
- NCT06016517
- Testing
- Etanercept, Adalimumab, Upadacitinib
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Tufts Medical Center
Adult Non-infectious Uveitis
A Multicenter, Open-label Study on the Efficacy and Safety of Tebiovio® (Adalimumab) in Treating Chinese Children With Severe Plaque Psoriasis
This study is a real-world clinical research on adalimumab. The project plans to enroll 30 subjects. The safety and efficacy of adalimumab injection for adult non-infectious uveitis are being investigated.
- Trial name
- NCT07663331
- Testing
- TyboWe® Adalimumab Injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Juvenile Idiopathic Arthritis Associated Uveitis, Uveitis, Anterior
Adalimumab Dose Adjustment for Pediatric Uveitis Treatment Trial
The goal of this clinical trial is to learn whether children and young adults with well-controlled juvenile idiopathic arthritis (JIA)-associated uveitis or chronic anterior uveitis can safely take adalimumab (or biosimilar)…
- Trial name
- ADAPT (NCT07699107)
- Testing
- Adalimumab/Biosimilar
- Where
- 18 sites in United States, Italy and 1 more
- Volunteers
- 160 people
- Sponsor
- Nisha Acharya
Uveitis, Chronic Disease
Therapeutic Drug Monitoring-baSed adalimuMab De-escalatiOn in nOn-infecTious cHronic Uveitis
Uveitis and its complications are thought to account for 10 to 15% of preventable blindness in Western countries. The diagnosis of chronic non-infectious uveitis (CNUI) can be made after exclusion of pseudo uveitis or infectious…
- Trial name
- SMOOTH (NCT06390436)
- Testing
- Blood sample, Adalimumab Injection
- Where
- 11 sites in France
- Volunteers
- 320 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne